anti pperk  (MedChemExpress)

Journal: Journal of Advanced Research

Article Title: Short-chain fatty acid butyrate against TMAO activating endoplasmic-reticulum stress and PERK/IRE1-axis with reducing atrial arrhythmia

doi: 10.1016/j.jare.2024.08.009

Figure Lengend Snippet: SB supplement ameliorated TMAO-mediated activation of ER stress signaling and dysregulation of ionic signaling. (A) and (B) Representative images and statistical data show the expression of pPERK, PERK, pIRE1α, IRE1α, pNF-κB, NF-κB, pIP3R, IP3R, NCX, Kv1.5, and β-actin in HL-1 cells from control group (n = 3), TMAO treated (n = 3), SB treated (n = 3), and TMAO combined with SB treated group (n = 3) in three independent experiments. β-Actin was used as a loading control. * P < 0.05. ** P < 0.01. TMAO versus control or SB or TMAO combined with SB treatment.

Article Snippet: Additionally, the atrial sections were incubated with primary antibodies against pPERK (#3179, Cell Signaling Technology), pIRE1α (NB100-2323, Novus), and pNF-κB (ab86299, Abcam).

Techniques: Activation Assay, Expressing, Control

Journal: Journal of Advanced Research

Article Title: Short-chain fatty acid butyrate against TMAO activating endoplasmic-reticulum stress and PERK/IRE1-axis with reducing atrial arrhythmia

doi: 10.1016/j.jare.2024.08.009

Figure Lengend Snippet: SB supplement ameliorated TMAO-mediated overexpression of ER stress signaling and pNF-κB in HL-1 cells. (A) and (B) show the representative images and statistical data of pPERK, pIRE1α, pNF-κB, and ER marker-Calnexin expression in HL-1 cells through cellular immunostaing assay in control group (n = 3), TMAO treated (n = 3), SB treated (n = 3), and TMAO combined with SB treated group (n = 3) in three independent experiments. (bar, 25 μm). ** P < 0.01. TMAO versus control or SB or TMAO combined with SB treatment.

Article Snippet: Additionally, the atrial sections were incubated with primary antibodies against pPERK (#3179, Cell Signaling Technology), pIRE1α (NB100-2323, Novus), and pNF-κB (ab86299, Abcam).

Techniques: Over Expression, Marker, Expressing, Control

Journal: Journal of Advanced Research

Article Title: Short-chain fatty acid butyrate against TMAO activating endoplasmic-reticulum stress and PERK/IRE1-axis with reducing atrial arrhythmia

doi: 10.1016/j.jare.2024.08.009

Figure Lengend Snippet: SB supplement ameliorated atrial fibrosis and PERK/IRE1α/NF-κB axis of TMAO-treated mice. The expression of atrial fibrosis (blue area) was detected by Masson's staining and immunostaining of pPERK, pIRE1α, and pNF-κB in the atrium tissues derived from mice gavage with control (n = 5), TMAO (n = 5), and TMAO combined with SB (n = 5). The expressions of pPERK are indicated by hollow arrowheads. (bar, 25 μm). ** p < 0.01. TMAO treatment versus control group or TMAO combined with SB treated group. (For interpretation of the references to colour in this Fig. legend, the reader is referred to the web version of this article.)

Article Snippet: Additionally, the atrial sections were incubated with primary antibodies against pPERK (#3179, Cell Signaling Technology), pIRE1α (NB100-2323, Novus), and pNF-κB (ab86299, Abcam).

Techniques: Expressing, Staining, Immunostaining, Derivative Assay, Control